Pharmaceutical company Mylan NV (Nasdaq:MYL)(TASE:MYL) said on Friday that the shareholders of
Meda Aktiebolag (publ.) will tender all their shares in Mylan under the recommended public offer.
The total value of the offer for all
Meda shares, including
Meda net debt, is approximately SEK 83.6bn or USD 9.9bn, which represents a multiple of approximately 8.9x 2015 adjusted EBITDA with synergies.
"
Meda is a unique and strategic asset, with a high-quality workforce, which will add to our powerful, diversified and sustainable global platform," Mylan executive chairman Robert Coury said in a statement.
According to
Meda, this nomination committee has been appointed as per the specifications of its 2015b annual general meeting.
Jeff Cohen:
Meda AB is a $1.7 billion international specialty pharmaceutical company focused on allergy/asthma, pain management, dermatology and specialty OTC products.
"This is by far
Meda's largest product and one of the products that's actually showing growth," Jenni Routtinen, an analyst at ABG Sundal Collier, said.
Information about environmental schemes funded under SMAP and other
MEDA and EU programmes is available on a special Internet portal launched on June 16.
The former
MEDA countries Cyprus and Malta will bring an EU influence to bear on the economic area in terms of the exploitation of the Mediterranean's marine resources.
M2 EQUITYBITES-August 8, 2016-Mylan Closes USD 7.2bn Acquisition of Swedish Drugmaker
Meda Aktiebolag